Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...

The high-profile obesity and diabetes products Wegovy and Ozempic, from Danish healthcare company Novo Nordisk, will see a significant global development on Friday — as a patent on its active ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

HYDERABAD: A surge in the unsupervised use of popular diabetes and weight-loss drugs in Hyderabad has raised alarm among doctors, who warn that social media trends and peer influence are pushing many ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

In a shot in the arm for India’s high-growth weight-loss medicines market, generic versions of Danish drugmaker Novo Nordisk’s blockbuster drug semaglutide will hit the shelves on Saturday, with price ...